Castle Biosciences (CSTL) Revenue & Revenue Breakdown
Castle Biosciences Revenue Highlights
Latest Revenue (Y)
$219.79M
Latest Revenue (Q)
$87.00M
Main Segment (Y)
Dermatologic
Castle Biosciences Revenue by Period
Castle Biosciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $219.79M | 60.38% |
| 2022-12-31 | $137.04M | 45.65% |
| 2021-12-31 | $94.08M | 50.18% |
| 2020-12-31 | $62.65M | 20.79% |
| 2019-12-31 | $51.87M | 127.62% |
| 2018-12-31 | $22.79M | 65.67% |
| 2017-12-31 | $13.75M | - |
Castle Biosciences generated $219.79M in revenue during NA 2023, up 60.38% compared to the previous quarter, and up 964.59% compared to the same period a year ago.
Castle Biosciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $87.00M | 19.22% |
| 2024-03-31 | $72.97M | 10.37% |
| 2023-12-31 | $66.12M | 7.52% |
| 2023-09-30 | $61.49M | 22.65% |
| 2023-06-30 | $50.14M | 19.27% |
| 2023-03-31 | $42.04M | 9.65% |
| 2022-12-31 | $38.34M | 3.59% |
| 2022-09-30 | $37.01M | 6.24% |
| 2022-06-30 | $34.84M | 29.74% |
| 2022-03-31 | $26.85M | 7.24% |
| 2021-12-31 | $25.04M | 6.66% |
| 2021-09-30 | $23.48M | 3.15% |
| 2021-06-30 | $22.76M | -0.24% |
| 2021-03-31 | $22.81M | 31.87% |
| 2020-12-31 | $17.30M | 13.68% |
| 2020-09-30 | $15.22M | 19.68% |
| 2020-06-30 | $12.71M | -27.00% |
| 2020-03-31 | $17.42M | -1.23% |
| 2019-12-31 | $17.64M | 19.36% |
| 2019-09-30 | $14.77M | 37.59% |
| 2019-06-30 | $10.74M | 23.19% |
| 2019-03-31 | $8.72M | -23.78% |
| 2018-12-31 | $11.44M | 208.10% |
| 2018-09-30 | $3.71M | -6.73% |
| 2018-06-30 | $3.98M | 8.77% |
| 2018-03-31 | $3.66M | - |
Castle Biosciences generated $87.00M in revenue during Q2 2024, up 19.22% compared to the previous quarter, and up 206.97% compared to the same period a year ago.
Castle Biosciences Revenue Breakdown
Castle Biosciences Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Dermatologic | $183.38M | $124.81M | $85.75M |
| Service, Other | - | $12.23M | $8.33M |
Castle Biosciences's latest annual revenue breakdown by segment (product or service), as of Dec 23: Dermatologic (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dermatologic | $68.83M | $59.33M | $53.28M | $51.15M | $43.03M | $35.91M | $34.65M | $33.92M | $31.90M | $24.34M |
| Service, Other | - | - | - | - | - | - | $3.69M | $3.09M | $2.94M | $2.51M |
Castle Biosciences's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Dermatologic (100.00%).
Castle Biosciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| NTRA | Natera | $1.08B | $413.35M |
| GTH | Genetron | $650.71M | $201.32M |
| GH | Guardant Health | $563.95M | $177.24M |
| BNR | Burning Rock Biotech | $537.43M | $125.62M |
| CDNA | CareDx | $280.32M | $92.27M |
| LMDX | LumiraDx | $254.48M | $21.00M |
| TWST | Twist Bioscience | $245.11M | $81.46M |
| CSTL | Castle Biosciences | $219.79M | $87.00M |
| OLK | Olink AB (publ) | $169.91M | $28.59M |
| FONR | FONAR | $98.65M | $25.72M |
| PSNL | Personalis | $73.48M | $19.52M |
| STIM | Neuronetics | $71.35M | $16.45M |
| XGN | Exagen | $52.55M | $15.06M |
| BDSX | Biodesix | $49.09M | $14.82M |
| ENZ | Enzo Biochem | $31.06M | $8.02M |
| SERA | Sera Prognostics | $306.00K | - |
CSTL Revenue FAQ
What is Castle Biosciences’s yearly revenue?
Castle Biosciences's yearly revenue for 2023 was $219.79M, representing an increase of 60.38% compared to 2022. The company's yearly revenue for 2022 was $137.04M, representing an increase of 45.65% compared to 2021. CSTL's yearly revenue for 2021 was $94.08M, representing an increase of 50.18% compared to 2020.
What is Castle Biosciences’s quarterly revenue?
Castle Biosciences's quarterly revenue for Q2 2024 was $87M, a 19.22% increase from the previous quarter (Q1 2024), and a 73.53% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $72.97M, a 10.37% increase from the previous quarter (Q4 2023), and a 73.59% increase year-over-year (Q1 2023). CSTL's quarterly revenue for Q4 2023 was $66.12M, a 7.52% increase from the previous quarter (Q3 2023), and a 72.47% increase year-over-year (Q4 2022).
What is Castle Biosciences’s revenue growth rate?
Castle Biosciences's revenue growth rate for the last 3 years (2021-2023) was 133.61%, and for the last 5 years (2019-2023) was 323.77%.
What are Castle Biosciences’s revenue streams?
Castle Biosciences's revenue streams in c 23 are Dermatologic
What is Castle Biosciences’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Castle Biosciences was Dermatologic. This segment made a revenue of $183.38M, representing 100.00% of the company's total revenue.